Yu.A. Kandrashkina, E.A. Orlova
Penza Institute for Advanced Training of Doctors is a branch of the FSBEI CPE «RMACPE» of the Ministry of Health
of the Russian Federation, Stasova Street, 8a, Penza, 440060, Russian Federation

Introduction. An increase in the number of patients with atopic dermatitis (AD) among pregnant women is recorded annually. However, the pathogenesis of AD during pregnancy is not fully understood. Exacerbations of AD during pregnancy require in-depth study, since at the moment there are no uniform recommendations for the treatment and management of such patients. The aim of the study. To study the role of cytokines (IL-31 and IL-33), neuropeptide – substance P (SP) and cortisol in the pathogenesis of AD during pregnancy before and after combined topical treatment. Material and methods. The study included 110 patients, including 70 pregnant women with exacerbation of AD, 20 – non-pregnant women with exacerbation of AD, 20 – healthy pregnant women. A group of pregnant women with exacerbation of AD received combined therapy "emollient + topical antipruritic agent" for 30 days. Patients were assessed in dynamics: control of symptoms and severity of AD (SCORAD index), IL-31 and IL-33, SP, cortisol. Statistical processing was carried out using the Statistica 6.0 software package. Results. When assessing the severity of AD, no significant differences were found between the groups. In the group of pregnant women with exacerbation, higher levels of IL-31, IL-33, cortisol, and SP were noted. At the end of a 30-day course of treatment for exacerbation of AD during pregnancy with a combination of "emollient + topical antipruritic agent", a significant change in the SCORAD index, IL-31, IL-33 and cortisol was recorded. Conclusion. Exacerbation of AD during pregnancy is accompanied by more pronounced changes in neuro-immunological parameters (IL-31 and IL-33, SP), as well as in the level of the stress hormone cortisol than in the control groups. The combination "emollient + topical antipruritic agent" in the course of the study showed clinical efficacy in eliminating the skin inflammatory process and contributed to a decrease in neuroimmune parameters.
atopic dermatitis, pregnancy, interleukins, substance P, treatment

Список литературы: 
  1. Иванов О.Л., Львов А.Н., Миченко А.В. Атопический дерматит: современные представления. Русский медицинский журнал. 2007; 19: 1362. [Ivanov O.L., L'vov A.N., Michenko A.V. Atopic dermatitis: modern concepts. Russkij medicinskij zhurnal. 2007; 19: 1362 (In Russian)]
  2. White S., Philips R., Neill M.M., Kelly E. Pregnancy-specific skin disorders. Skin Therapy Lett. 2014; 19 (5): 7–9.
  3. Домбровская Д.К., Кравченко Э.В. Атопический дерматит и беременность. Журнал акушерства и женских болезней. 2012; 5: 112–4. [Dombrovskaya D.K., Kravchenko E.V. Atopic dermatitis and pregnancy. Zhurnal akusherstva i zhenskih boleznej. 2012; 5: 112–4 (In Russian)]
  4. Mollanazar N.K., Smith P.K., Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016; 51: 263–92.
  5. Каштальян О.А., Ушакова Л.Ю. Цитокины как универсальная система регуляции. Медицинские новости. 2017; 9: 3–7. [Kashtal'yan O.A., Ushakova L.Yu. Cytokines as a universal regulatory system. Medicinskie novosti. 2017; 9: 3–7 (In Russian]
  6. Steinhoff M., Buddenkotte J., Lerner E.A. Role of mast cells and basophils in pruritus. Immunol Rev. 2018; 282 (1): 248–64. DOI: 10.1111/imr.12635
  7. Imai Y. Interleukin-33 in atopic dermatitis. J. Dermatol. Sci. 2019; 96 (1): 2–7.
  8. Maier E., Werner D., Duschl A., Bohle B., Horejs-Hoeck J. Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-κB-dependent way. J. Immunol. 2014; 193 (2): 645–54.
  9. Cevikbas F., Wang X., Akiyama T. et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. J Allergy ClinImmunol. 2014; 133 (2): 448–60.
  10. Mu Z., Zhao Y., Liu X., Chang C., Zhang J. Molecular biology of atopic dermatitis. Clin Rev Allergy Immunol. 2014; 47 (2): 193–218.
  11. Ревякина В.А., Агафонов А.С., Сенцова Т.Б., Фабрика М.П. Участие нейропептидов и β- эндорфина в патогенезе атопического дерматита. Оценка эффективности левоцетирезина и его влияние на уровни нейропептидов у детей с атопическим дерматитом. Российский аллергологический журнал. 2010; 2: 72–8. [Revyakina V.A., Agafonov A.S., Sencova T.B., Fabrika M.P. Participation of neuropeptides and β-endorphins in the pathogenesis of atopic dermatitis. Evaluation of the efficacy of levocetiresin and its effect on neuropeptide levels in children with atopic dermatitis. Rossijskij allergologicheskij zhurnal. 2010; 2: 72–8 (In Russian)]
  12. Sanders K.M., Akiyama T. The vicious cycle of itch and anxiety. NeurosciBiobehav Rev. 2018; 87: 17–26.
  13. Lin T.K., Zhong L., Santiago J.L. Association between Stress and the HPA Axis in the Atopic Dermatitis. Int J. Mol. Sci. 2017; 18 (10): 2131.
  14. Довжикова И.В. Кортизол при беременности (обзор литературы). Acta Biomedica Scientifica. 2010; 6 (1): 226–9. [Dovzhikova I.V. Cortisol during pregnancy (literature review). Acta Biomedica Scientifica. 2010; 6 (1): 226–9 (In Russian)]
  15. Клинические рекомендации по атопическому дерматиту 2020 г. Режим доступа: [Clinical practice guidelines for atopic dermatitis 2020 y. (In Russian)]